Critical Role of Voltage Application Points in “Analog” and “Digital” Electrospray Ionization Mass Spectrometry by Min-Min Hung (21096009)

Fig 4 - by Hyuk Sung Yoon (20208672)

R346K Mutation in the <i>Mu</i> Variant of SARS-CoV‑2 Alters the Interactions with Monoclonal Antibodies from Class 2: A Free Energy Perturbation Study by Filip Fratev (1799740)

“…The <i>Mu</i> variant of SARS-CoV-2 has been recently classified as a variant of interest (VOI) by the World Health Organization (WHO) but limited data are available at the moment. …”

R346K Mutation in the <i>Mu</i> Variant of SARS-CoV‑2 Alters the Interactions with Monoclonal Antibodies from Class 2: A Free Energy Perturbation Study by Filip Fratev (1799740)

“…The <i>Mu</i> variant of SARS-CoV-2 has been recently classified as a variant of interest (VOI) by the World Health Organization (WHO) but limited data are available at the moment. …”

Fig 4 - by Leena Inkilä (20614460)

Mean scores of IB-DE, IH-DE, and IB-DE items in Sample 1 and Sample 2 as well as women and men across the samples. by Aistė Ambrasė (22505574)

Poly(ionic liquid) Electrolytes for a Switchable Silver Mirror by Xiao Hou (3228048)

“…These findings were used to guide fabrication of a 50 cm² mirror dynamic window and flexible display. …”

Effects of different concentrations of propofol on the survival rate of zebrafish embryos and larvae. by Yali Ge (417371)

DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet6_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet4_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

S1 Data - by Jordan A. Gunning (18143970)

“…Specifically, total immune cells (CD45+) decrease at days 2 and 5 following IR, macrophages (F4/80+CD11b+) decrease at day 2 and 5 and increase at day 30, while neutrophils (Ly6G+CD11b+) significantly increase at day 30 following IR. …”

Example for a parametrically manipulated baby. by Sarah K. C. Holtfrerich (3353693)

Basic characteristics of the studies included. by Renáta Kiss-Miki (20760127)

“…Odd ratios (OR) and mean differences (MD) with 95% confidence intervals (CI) were calculated using a random-effects model. …”

List_of_studies_identified_31-JAN-2025. by Renáta Kiss-Miki (20760127)

“…Odd ratios (OR) and mean differences (MD) with 95% confidence intervals (CI) were calculated using a random-effects model. …”

Data_extraction_table_31-JAN-2025. by Renáta Kiss-Miki (20760127)

“…Odd ratios (OR) and mean differences (MD) with 95% confidence intervals (CI) were calculated using a random-effects model. …”

S5 Table - by Gastón F. Alfaro (9080189)

S5 Fig - by Gastón F. Alfaro (9080189)